Managing Children with Bronchopulmonary Dysplasia
A. A. Baranov,
L. S. Namazova-Baranova,
N. N. Volodin,
I. V. Davydova,
D. U. Ovsyannikov,
D. O. Ivanov,
E. V. Boytsova,
G. V. Yatsik,
A. G. Antonov,
O. V. Ionov,
A. U. Ryndin,
V. A. Grebennikov,
I. G. Soldatova,
A. I. Chubarova https://doi.org/10.15690/pf.v13i4.1603
Abstract
Bronchopulmonary dysplasia is one of the most significant early childhood chronic respiratory diseases. The article features modern approaches to preventing, diagnosing and treating broncho-pulmonary dysplasia, as well as ways of preventing complications and undesirable disease outcomes in patients older than 3 years. Members of professional associations — Union of Pediatricians of Russia and Russian Association of Perinatal Medicine Specialists — have summarized the experience of managing this category of patients at leading Russian pediatric centers according to the principles of evidence-based medicine and have provided scientific and practical data corresponding to the world level of knowledge with regard to the present problem.
About the Authors
A. A. Baranov
Scientific Center of Children’s Health;
Pirogov Russian National Research Medical University
Russian Federation
Moscow
Russian Federation
Moscow
L. S. Namazova-Baranova
Scientific Center of Children’s Health;
Pirogov Russian National Research Medical University;
Sechenov First Moscow State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
N. N. Volodin
D. Rogachev Federal Scientific-Clinical Center of Child Hematology, Oncology and Immunology
Russian Federation
Moscow
Russian Federation
Moscow
I. V. Davydova
Scientific Center of Children’s Health;
Sechenov First Moscow State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
D. U. Ovsyannikov
Peoples’ Friendship University
Russian Federation
Moscow
Russian Federation
Moscow
D. O. Ivanov
St. Petersburg State Pediatric Medical University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
E. V. Boytsova
Scientific Research Institute of Pulmonology at the I.P. Pavlov St. Petersburg State Medical University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
G. V. Yatsik
Scientific Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
A. G. Antonov
V.I. Kulakov Scientific Center of Obstetrics, Gynaecology and Perinatology
Russian Federation
Moscow
Russian Federation
Moscow
O. V. Ionov
V.I. Kulakov Scientific Center of Obstetrics, Gynaecology and Perinatology
Russian Federation
Moscow
Russian Federation
Moscow
A. U. Ryndin
V.I. Kulakov Scientific Center of Obstetrics, Gynaecology and Perinatology
Russian Federation
Moscow
Russian Federation
Moscow
V. A. Grebennikov
Pirogov Russian National Research Medical University
Russian Federation
Moscow
Russian Federation
Moscow
I. G. Soldatova
Pirogov Russian National Research Medical University
Russian Federation
Moscow
Russian Federation
Moscow
A. I. Chubarova
Pirogov Russian National Research Medical University
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Современные подходы к профилактике, диагностике и лечению бронхолегочной дисплазии / Под ред. А.А. Баранова, Л.С. Намазовой-Барановой, И.В. Давыдовой. — М.: ПедиатрЪ; 2013. 176 с.
2. [Sovremennye podkhody k profilaktike, diagnostike i lecheniyu bronkholegochnoi displazii. Ed by A.A. Baranov, L.S. Namazova-Baranova, I.V. Davydova. Moscow: Pediatr; 2013. 176 p. (In Russ).]
3. Овсянников Д.Ю. Система оказания медицинской помощи детям, страдающим бронхолегочной дисплазией. Руководство для практикующих врачей / Под ред. Л.Г. Кузьменко. — М.: МДВ; 2010. — 152 с. [Ovsyannikov DYu. Sistema okazaniya meditsinskoi pomoshchi detyam, stradayushchim bronkholegochnoi displaziei. Rukovodstvo dlya praktikuyushchikh vrachei. Ed by L.G. Kuz’menko. Moscow: MDV; 2010. 152 p. (In Russ).]
4. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116(6):1353–1360. doi: 10.1542/peds.2005-0249.
5. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723–1729. doi: 10.1164/ajrccm.163.7.2011060.
6. Walsh MC, Yao Q, Gettner P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004;114(5): 1305–1311. doi: 10.1542/peds.2004-0204.
7. Allen J, Zwerdling R, Ehrenkranz R, et al. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med. 2003;168(3):356–396. doi: 10.1164/rccm.168.3.356.
8. Авдеев С.Н. Дыхательная недостаточность: определение, классификация, подходы к диагностике и терапии. В кн.: Респираторная медицина / Под ред. А.Г. Чучалина. — М.: ГЭОТАР–Медиа; 2007. — Т. 2. — С. 658–668. [Avdeev SN. Dykhatel’naya nedostatochnost’: opredelenie, klassifikatsiya, podkhody k diagnostike i terapii. In: Respiratornaya meditsina. Ed by A.G. Chuchalin. Moscow: GEOTAR–Media; 2007. V.2. p. 658–668. (In Russ).]
9. Charafeddine L, D’Angio CT, Phelps DL. Atypical chronic lung disease patterns in neonates. Pediatrics. 1999;103(4):759–765. doi: 10.1542/peds.103.4.759.
10. Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol. 2003;8(1):63–71. doi: 10.1016/s1084-2756(02)00192-6.
11. Greenough A, Kavvadia V, Johnson AH, et al. A simple chest radiograph score to predict chronic lung disease in prematurely born infants. Br J Radiol. 1999;72(858):530–533. doi: 10.1259/bjr.72.858.10560333.
12. Патент на изобретение № 2401066. Яцык Г.В., Давыдова И.В., Кустова О.В. и др. «Способ оценки степени тяжести бронхолегочной дисплазии». Зарегистрирован в Государственном реестре изобретений РФ от 10.10.2010. [Patent RUS № 2401066 Yatsyk G.V., Davydova I.V., Kustova O.V., et al. «Sposob otsenki stepeni tyazhesti bronkholegochnoi displazii». Registered in Gosudarstvennom reestre izobretenii RF dated October 10, 2010. (In Russ).]
13. Румянцев А.Г., Григорянц Л.Я. Дифференциальная диагностика и терапия анемии новорожденных. В кн.: Практическое руководство по детским болезням. Гематология / Онкология детского возраста. Т. IV / Под ред. А.Г. Румянцева и Е.В. Самочатовой. — М.: Медпрактика–М; 2004. — С. 234–276. [Rumyantsev AG, Grigoryants LYa. Differentsial’naya diagnostika i terapiya anemii novorozhdennykh. In: Prakticheskoe rukovodstvo po detskim boleznyam. Gematologiya. Onkologiya detskogo vozrasta. V.4. Ed by A.G. Rumyantsev, E.V. Samochatova. Moscow: Medpraktika–M; 2004. p. 234–276. (In Russ).]
14. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–2537. doi: 10.1093/eurheartj/ehp297.
15. Abman SH. Approach to the child with pulmonary hypertension and bronchopulmonary dysplasia. Advances in pulmonary hypertension. 2011;10(2):98–103.
16. Овсянников Д.Ю., Дегтярева Е.А. Легочная гипертензия и легочное сердце — осложнения бронхолегочной дисплазии // Вопросы диагностики в педиатрии. — 2013. — Т. 5. — № 4. — С. 5–13. [Ovsyannikov DYu, Degtyareva EA. Pulmonary hypertension and cor pulmonale as complications of bronchopulmonary dysplasia. Voprosy diagnostiki v pediatrii. 2013;5(4):5–13. (In Russ).]
17. Cerro MJ, Abman S, Diaz G, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1(2):286–298. doi: 10.4103/2045-8932.83456.
18. Петрова Н.А., Добродеева И.В., Пальчик А.Б. и др. Апноэ и периодическое дыхание у новорожденных детей с бронхолегочной дисплазией // Педиатрия. — 2009. — Т.87. — №1. — С. 13–18. [Petrova NA, Dobrodeeva IV, Pal’chik AB, et al Apnoe i periodicheskoe dykhanie u novorozhdennykh detei s bronkholegochnoi displaziei. Pediatriia. 2009;87(1):13–18. (In Russ).]
19. Намазова-Баранова Л.С., Турти Т.В., Давыдова И.В. и др. Флоуметрия спокойного дыхания у детей первого года жизни. Методические рекомендации. — М.: ПедиатрЪ; 2012. — 32 с. [Namazova-Baranova LS, Turti TV, Davydova IV, et al. Floumetriya spokoinogo dykhaniya u detei pervogo goda zhizni Metodicheskie rekomendatsii. Moscow: Pediatr; 2012. 32 p. (In Russ).]
20. Неонатальная хирургия / Под ред. Ю.Ф. Исакова, Н.Н. Володина, А.В. Гераськина. — М.: Династия; 2011. — 680 с. [Neonatal’naya khirurgiya. Ed by Yu.F. Isakov, N.N. Volodin, A.V. Geras’kin. Moscow: Dinastiya; 2011. 680 p. (In Russ).]
21. Овсянников Д.Ю., Беляшова М.А., Крушельницкий А.А., и др. Синдром Вильсона-Микити — редкое хроническое заболевание легких новорожденных // Педиатрия. — 2014. — Т. 93. — № 1. — С. 38–42. [Ovsyannikov DYu, Belyashova MA, Krushel’nitskii AA, et al. Sindrom Vil’sona-Mikiti — redkoe khronicheskoe zabolevanie legkikh novorozhdennykh. Pediatriia. 2014;93(1):38–42. (In Russ).]
22. Network SSGotEKSNNR, Finer NN, Carlo WA, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362(21):1970–1979. doi: 10.1056/NEJMoa0911783.
23. Sandri F, Plavka R, Ancora G, et al. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics. 2010;125(6):e1402–1409. doi: 10.1542/peds.2009-2131.
24. Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2012(3):CD000510. doi: 10.1002/14651858.CD000510.pub2.
25. Stevens TP, Blennow M, Myers EH, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007(4):CD003063. doi: 10.1002/14651858.CD003063.pub3.
26. Verder H, Robertson B, Greisen G, et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group. N Engl J Med. 1994;331(16):1051–1055. doi: 10.1056/NEJM199410203311603.
27. Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update. Neonatology. 2013;103(4):353–368. doi: 10.1159/000349928.
28. Morley CJ. Volume-limited and volume-targeted ventilation. Clin Perinatol. 2012;39(3):513-523. doi: 10.1016/j.clp.2012.06.016.
29. Wheeler K, Klingenberg C, McCallion N, et al. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev. 2010(11):CD003666. doi: 10.1002/14651858.CD003666.pub3.
30. Erickson SJ, Grauaug A, Gurrin L, Swaminathan M. Hypocarbia in the ventilated preterm infant and its effect on intraventricular haemorrhage and bronchopulmonary dysplasia. J Paediatr Child Health. 2002;38(6):560–562. doi: 10.1046/j.1440-1754.2002.00041.x.
31. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000;105(2):295–310. doi: 10.1542/peds.105.2.295.
32. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygensaturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003;349(10):959–967. doi: 10.1056/NEJMoa023080.
33. Network SSGotEKSNNR. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362(21):1959–1969. doi: 10.1056/NEJMoa0911781.
34. Stenson B, Brocklehurst P, Tarnow-Mordi W. Increased 36-week survival with high oxygen saturation target in extremely preterm infants. N Engl J Med. 2011;364(17):1680–1682. doi: 10.1056/NEJMc1101319.
35. Nievas FF, Chernick V. Bronchopulmonary dysplasia (chronic lung disease of infancy): an update for the pediatrician. Clin Pediatr (Phila). 2002;41(2):77–85. doi: 10.1177/000992280204100202.
36. Комитет по стандартам медицинской помощи BTS. Подготовка больных с респираторной патологией к авиаперелетам: рекомендации Британского торакального общества // Пульмонология. — 2005. — № 5. — С. 13–34. [Komitet po standartam meditsinskoi pomoshchi BTS podgotovka bol’nykh s respiratornoi patologiei k aviapereletam: rekomendatsii Britanskogo torakal’nogo obshchestva. Pul’monologiya. 2005;(5):13–34. (In Russ).]
37. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–2121. doi: 10.1056/NEJMoa054065.
38. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev. 2010(12):CD000139. doi: 10.1002/14651858.CD000139.pub2.
39. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2010(1):CD001146. doi: 10.1002/14651858.CD001146.pub3.
40. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009(1):CD001145. doi: 10.1002/14651858.CD001145.pub2.
41. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115(3):655–661. doi: 10.1542/peds.2004-1238.
42. Бабак О.А., Воронцова Ю.Н., Геппе Н.А. и др. Бронхолегочная дисплазия. Методические рекомендации / Под ред. Н.Н. Володина. — М.: Издательство ГОУ ВПО РГМУ Росздрава; 2010. — 56 с. [Babak OA, Vorontsova YuN, Geppe NA, et al. Bronkholegochnaya displaziya. Metodicheskie rekomendatsii. Ed by N.N. Volodin. Moscow: Izdatel’stvo GOU VPO RGMU Roszdrava; 2010. 56 p. (In Russ).]
43. Doyle LW, Davis PG, Morley CJ, et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117(1):75–83. doi: 10.1542/peds.2004-2843.
44. Onland W, Offringa M, De Jaegere AP, van Kaam AH. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebocontrolled trials. Pediatrics. 2009;123(1):367–377. doi: 10.1542/peds.2008-0016.
45. Kersbergen KJ, de Vries LS, van Kooij BJ, et al. Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants. J Pediatr. 2013;163(3):666–671 e661. doi: 10.1016/j.jpeds.2013.04.001.
46. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev. 2003(2):CD002057. doi: 10.1002/14651858.CD002057.
47. Shah VS, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2012;(5):CD001969. doi: 10.1002/14651858.CD001969.pub3.
48. Dugas MA, Nguyen D, Frenette L, et al. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics. 2005; 115(5):e566–572. doi: 10.1542/peds.2004-0951.
49. Pantalitschka T, Poets CF. Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia. Pediatr Pulmonol. 2006; 41(8):703-708. doi: 10.1002/ppul.20467.
50. Овсянников Д.Ю., Дегтярева Е.А. Клинико-фармако эконо мический анализ терапии бронхолегочной дисплазии у детей первых трех лет жизни // Российский педиатрический журнал. — 2008. — № 4. — С. 10–16. [Ovsyannikov DYu, Degtyareva EA. Clinico pharmacoeconomic analysis of therapy for bronchopulmonary dysplasia in children of the first three years of life. Rossiiskii pediatricheskii zhurnal. 2008;(4):10–16. (In Russ).]
51. Давыдова И.В., Яцык Г.В., Бершова Т.В. и др. Матриксные металлопротеиназы как маркеры формирования бронхолегочной дисплазии у детей // Пульмонология. — 2009. — №4. — С. 80–84. [Davydova IV, Yatsyk GV, Bershova TV, et al. Matriksnye metalloproteinazy kak markery formirovaniya bronkholegochnoi displazii u detei. Pul’monologiya. 2009;(4):80–84. (In Russ).]
52. Ng G, da Silva O, Ohlsson A. Bronchodilation for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2001;(23):CD003214. doi: 10.1002/14651858.cd003214.pub2.
53. Yuksel B, Greenough A, Maconochie I. Effective bronchodilator treatment by a simple spacer device for wheezy premature infants. Arch Dis Child. 1990;65(7):782–785. doi: 10.1136/adc.65.7.782.
54. Wilkie RA, Bryan MH. Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease. J Pediatr. 1987;111(2):278–282. doi: 10.1016/s0022-3476(87)80087-2.
55. Володин Н.Н. Актуальные проблемы неонатологии. — М.: ГЭОТАР–Мед; 2004. — С. 177–190. [Volodin NN. Aktual’nye problemy neonatologii. Moscow: GEOTAR–Med; 2004. p. 177–190. (In Russ).]
56. American Academy of Pediatrics Subcommittee on D, Management of B. Diagnosis and management of bronchiolitis. Pediatrics. 2006; 118(4):1774–1793. doi: 10.1542/peds.2006-2223.
57. Schweich PJ, Hurt TL, Walkley EI, et al. The use of nebulized albuterol in wheezing infants. Pediatr Emerg Care. 1992;8(4):184–188. doi: 10.1097/00006565-199208000-00003.
58. Schuh S, Canny G, Reisman JJ, et al. Nebulized albuterol in acute bronchiolitis. J Pediatr. 1990;117(4):633–637. doi: 10.1016/s0022-3476(05)80706-1.
59. Pandit PB, Dunn MS, Kelly EN, Perlman M. Surfactant replacement in neonates with early chronic lung disease. Pediatrics. 1995;95(6): 851–854.
60. Checchia PA, Nalysnyk L, Fernandes AW, et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011;12(5):580–588. doi: 10.1097/PCC.0b013e3182070990.
61. Игнатьева В.И., Авксентьева М.В., Реброва О.Ю. и др. Клинико-экономический анализ результатов программы иммунопрофилактики РСВ-инфекции в эпидемический сезон 2012/2013 гг. в Москве // Педиатрическая фармакология. — 2013. — Т. 10. — № 6. — С. 17–26. [Ignat’eva VI, Avksentyeva MV, Rebrova OU, et al. A clinical and economical analysis of the results produced by the program of RSVinfection prophylaxis during the epidemiological season of 2012–2013 in Moscow. Pediatric pharmacology. 2013;10(6):17–26. (In Russ).] doi: 10.15690/pf.v10i6.892.
62. Баранов А.А., Давыдова И.В., Турти Т.В., Намазова-Баранова Л.С. и др. Иммунопрофилактика тяжелого течения респираторно-синцитиальной вирусной инфекции у детей с бронхолегочной дисплазией: результаты четырех эпидемических сезонов // Педиатрическая фармакология. —2012. — Т.9. — №6. — С. 48–52. [Baranov AA, Davydova IV, Turti TV, et al. Immunoprophylaxis of severe respiratorysyncytial viral infection in children with bronchopulmonary dysplasia: results of 4 epidemic seasons. Pediatric pharmacology. 2012;9(6): 48–52. (In Russ).] doi: 10.15690/pf.v9i6.518.
63. Янг Т., Мангум Б. Неофакс 2006. — М.: Веретея; 2006. — 332 с. [Yang T, Mangum B. Neofaks 2006. Moscow: Vereteya; 2006. 332 p. (In Russ).]
64. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009;154(3):379–384.e2. doi: 10.1016/j.jpeds.2008.09.021.
65. Дегтярева Е.А., Овсянников Д.Ю., Зайцева Н.О. и др. Легочная гипертензия и легочное сердце у детей с бронхолегочной дисплазией: факторы риска, диагностика, возможности терапии и профилактики // Педиатрия. — 2013. — №5. — С. 32–39. [Degtyareva EA, Ovsyannikov DYu, Zaitseva NO, et al. Legochnaya gipertenziya i legochnoe serdtse u detei s bronkholegochnoi displaziei: faktory riska, diagnostika, vozmozhnosti terapii i profilaktiki. Pediatriia. 2013;(5):32–39. (In Russ).]
66. Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009;155(6):841–847.e841. doi: 10.1016/j.jpeds.2009.06.012.
67. Таточенко В.К. Вакцинация недоношенных и маловесных детей // Педиатрическая фармакология. — 2013. — Т. 10. — № 4. — С. 30–36. [Tatochenko VK. Vaccination of premature/low-birth-weight children. Pediatric pharmacology. 2013;10(4):30–36. (In Russ).] doi: 10.15690/pf.v10i4.752.
68. Tommiska V, Heinonen K, Kero P, et al. A national two year follow up study of extremely low birthweight infants born in 1996–1997. Arch Dis Child Fetal Neonatal Ed. 2003;88(1):F29–35. doi:10.1136/fn.88.1.F29.
69. Столл Б. Дж., Клигман Р.М. Поражения дыхательных путей. В кн.: Педиатрия по Нельсону / Под ред. Р.Э. Бермана, Р.М. Клигмана, Х.Б. Джонсона. Пер. с англ. — М.: Рид Элсивер; 2009. — Т. 1. — С. 371–399. [Stoll BJ, RM Kliegman. Respiratory tract infections. In: Behrman RE, RM Kliegman, Jenson HB, editors. Nelson textbook of pediatrics. Transl. from English. Moscow: Rid Elsevier; 2009. V. 1. p. 371–399. (In Russ).]
70. Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120(6):1260–1269. doi: 10.1542/peds.2007-0971.
71. Бойцова Е.В., Богданова А.В., Овсянников Д.Ю. Последствия бронхолегочной дисплазии для респираторного здоровья детей, подростков и молодых взрослых // Вопросы диагностики в педиатрии. — 2013. — Т.5. — №1. — С. 5–11. [Boytsova EV, Bogdanova AV, Ovsyannikov DYu. The consequences of bronchopulmonary dysplasia for respiratory health of children, adolescents and young adults. Voprosy diagnostiki v pediatrii. 2013;5(1):5–11. (In Russ).]
Review
For citations:
Baranov A.A., Namazova-Baranova L.S., Volodin N.N., Davydova I.V., Ovsyannikov D.U., Ivanov D.O., Boytsova E.V., Yatsik G.V., Antonov A.G., Ionov O.V., Ryndin A.U., Grebennikov V.A., Soldatova I.G., Chubarova A.I. Managing Children with Bronchopulmonary Dysplasia. Pediatric pharmacology. 2016;13(4):319-333. (In Russ.) https://doi.org/10.15690/pf.v13i4.1603
Views:
1383
Email this article 